# T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

> **NCT00986557** · PHASE2 · UNKNOWN · sponsor: **University Hospital Birmingham** · enrollment: 78 (estimated)

## Conditions studied

- Graft Versus Host Disease
- Nonneoplastic Condition

## Interventions

- **BIOLOGICAL:** adoptive immunotherapy
- **BIOLOGICAL:** alemtuzumab
- **BIOLOGICAL:** in vitro-treated peripheral blood lymphocyte therapy
- **DRUG:** foscarnet sodium
- **DRUG:** ganciclovir
- **GENETIC:** polymerase chain reaction
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** infection prophylaxis and management
- **PROCEDURE:** peripheral blood stem cell transplantation
- **PROCEDURE:** standard follow-up care
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00986557
- **Lead sponsor:** University Hospital Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-09
- **Primary completion:** 2013-08
- **Final completion:** —
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00986557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00986557, "T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00986557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*